ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,423.63
-0.01%
Dow Jones
39,845.70
0.10%
Gold vs US Dollar
2,428.79
0.10%
Brent Oil
83.045
-0.58%
Bitcoin
70,329.36
-1.57%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. InflaRx NV (IFRX)

  7. InflaRx NV (IFRX) News

InflaRx NV (IFRX)

InflaRx NV
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:IFRX
DateTimeSourceHeadlineSymbolCompany
08/05/202413:43Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IFRXInflaRx NV
08/05/202412:30GlobeNewswire Inc.InflaRx Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:IFRXInflaRx NV
30/04/202412:30GlobeNewswire Inc.InflaRx to Host Virtual R&D Event on June 5, 2024 and Report First Quarter 2024 Results on May 8, 2024NASDAQ:IFRXInflaRx NV
24/04/202412:30GlobeNewswire Inc.InflaRx to Participate in Capital One Securities 1st Annual Biotech/Biopharma Disrupters EventNASDAQ:IFRXInflaRx NV
21/03/202411:00GlobeNewswire Inc.InflaRx Reports Full Year 2023 Results and Announces INF904 Development PlansNASDAQ:IFRXInflaRx NV
19/03/202411:30GlobeNewswire Inc.InflaRx to Announce Development Plans for INF904 and 2023 Financial Results on March 21, 2024NASDAQ:IFRXInflaRx NV
22/02/202412:30GlobeNewswire Inc.InflaRx Appoints Jan Medina as Head of Investor RelationsNASDAQ:IFRXInflaRx NV
25/01/202413:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IFRXInflaRx NV
25/01/202412:30GlobeNewswire Inc.InflaRx Announces Initiation of its Commitment Program for GOHIBIC®(vilobelimab) to Help Broaden Access for Eligible PatientsNASDAQ:IFRXInflaRx NV
04/01/202421:16Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IFRXInflaRx NV
04/01/202412:00GlobeNewswire Inc.InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904NASDAQ:IFRXInflaRx NV
06/11/202313:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IFRXInflaRx NV
06/11/202312:30GlobeNewswire Inc.InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma GangrenosumNASDAQ:IFRXInflaRx NV
01/11/202312:04Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IFRXInflaRx NV
01/11/202311:30GlobeNewswire Inc.InflaRx Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:IFRXInflaRx NV
11/09/202313:45Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IFRXInflaRx NV
11/09/202312:00GlobeNewswire Inc.InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904NASDAQ:IFRXInflaRx NV
30/08/202313:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IFRXInflaRx NV
30/08/202312:30GlobeNewswire Inc.InflaRx’s Marketing Authorization Application (MAA) for Vilobelimab for Treatment of Critically Ill COVID-19 Patients under Review by European Medicines Agency (EMA)NASDAQ:IFRXInflaRx NV
10/08/202313:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IFRXInflaRx NV
10/08/202312:30GlobeNewswire Inc.InflaRx Reports Second Quarter 2023 Financial Results & Operating UpdateNASDAQ:IFRXInflaRx NV
12/07/202321:01Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IFRXInflaRx NV
12/07/202305:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:IFRXInflaRx NV
30/06/202321:06Edgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:IFRXInflaRx NV
28/06/202313:31Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:IFRXInflaRx NV
28/06/202313:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:IFRXInflaRx NV
28/06/202312:30GlobeNewswire Inc.InflaRx Appoints Dr. Camilla Chong as Chief Medical OfficerNASDAQ:IFRXInflaRx NV
21/06/202313:30Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:IFRXInflaRx NV
21/06/202312:00GlobeNewswire Inc.InflaRx Announces Commercial Launch of Gohibic (vilobelimab) in the U.S. for the Treatment of Critically Ill COVID-19 PatientsNASDAQ:IFRXInflaRx NV
11/05/202312:30GlobeNewswire Inc.InflaRx Reports First Quarter 2023 Financial and Operating Results and Provides Business UpdateNASDAQ:IFRXInflaRx NV
 Showing the most relevant articles for your search:NASDAQ:IFRX

Your Recent History

LSE
POS
Plexus
LSE
TERN
Tern
LSE
VAL
Valirx
LSE
VAST
Vast Resources
LSE
BP.
Bp
LSE
SCLP
Scancell
LSE
PHE
Powerhouse Energy
LSE
GKP
Gulf Keystone Petroleum
LSE
SYME
Supply@me Capital
LSE
MIN
Minoan
LSE
TEK
Tekcapital
LSE
SOLG
Solgold
LSE
KEFI
Kefi Gold And Copper
LSE
LLOY
Lloyds Banking
LSE
SCE
Surface Transforms
LSE
CHLL
Chill Brands
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved